Vedolizumab for ulcerative colitis and Crohn’s disease

Vedolizumab (Entyvio) is licensed for the treatment of moderate to active ulcerative colitis and Crohn’s disease. Here we present the clinical data relating to its efficacy and adverse events and comment on its place in therapy.

Vedolizumab for ulcerative colitis and Crohns disease

Add yours ↓
Web design and marketing agency Leamington Spa